Joint ICGEB – ALS Society of Canada Symposium on inflammation and proteinopathy in ALS/FTD spectrum disorder

26 – 28 June, Rijeka, Croatia

The ICGEB aims at strengthening the research capability of its Members through a comprehensive training programme and approach to promoting biotechnology internationally. The active participation of ICGEB Member States nationals in the ICGEB Meetings and Courses is therefore highly encouraged. For more information on the terms of participation and funding opportunities for this event please access the meeting website or contact the local organisers directly.

The workshop will gather top experts in the field of neurodegeneration, neuroinflammation, animal models, clinical studies and emerging therapies in ALS/FTD and related fields. Young researchers will be greatly supported via selected oral presentations, poster sessions and networking opportunities.

Organiser:
Ivana Munitic (University of Rijeka, Department of Biotechnology, Croatia)

In collaboration with:

Deadline for receipt of applications:
16 March 2020
CALL FOR APPLICATIONS WILL OPEN 16 DECEMBER 2019

Follow the Events on Twitter: #ICGEBmeeting

Topics

ALS/FTD genetics and mechanisms, Proteinopathy in ALS/FTD, Immunity in ALS/FTD, Related brain disorders, Clinical studies, biomarkers and emerging therapies in ALS/FTD.

Participants

Basic and clinical researchers in the fields of neurodegeneration, neuroimmunology, neurodevelopment and related fields. Postdocs, clinical residents, PhD and Ms students are encouraged to participate. Poster sections will be organised and best abstracts selected for oral presentations.

Funding

Nationals of ICGEB Member States currently residing outside of Croatia are eligible to apply for a grant covering registration fee, twin-share accommodation and local hospitality during the meeting. An additional number of grants will be available to cover the registration fee, either partially or in full. Limited travel contribution towards the cost of international travel may aslo be available.